FLUORESCEIN ANGIOGRAPHY OF EXTREME PERIPHERAL RETINA AND RUBEOSIS IRIDIS IN PROLIFERATIVE DIABETIC RETINOPATHY

Retina ◽  
1999 ◽  
Vol 19 (4) ◽  
pp. 302-308 ◽  
Author(s):  
HIROKO TERASAKI ◽  
YOZO MIYAKE ◽  
MASAKO MORI ◽  
TOSHIMITU SUZUKI ◽  
MINEO KONDO
Keyword(s):  
Diabetic Retinopathy ◽  
Fluorescein Angiography ◽  
Proliferative Diabetic Retinopathy ◽  
Peripheral Retina ◽  
Rubeosis Iridis

FLUORESCEIN ANGIOGRAPHY OF EXTREME PERIPHERAL RETINA AND RUBEOSIS IRIDIS IN PROLIFERATIVE DIABETIC RETINOPATHY

Retina ◽  
1999 ◽  
Vol 19 (4) ◽  
pp. 302 ◽  
Author(s):  
HIROKO TERASAKI ◽  
YOZO MIYAKE ◽  
MASAKO MORI ◽  
TOSHIMITU SUZUKI ◽  
MINEO KONDO
Keyword(s):  
Diabetic Retinopathy ◽  
Fluorescein Angiography ◽  
Proliferative Diabetic Retinopathy ◽  
Peripheral Retina ◽  
Rubeosis Iridis

Analysis of quantitative correlations between microaneurysm, ischaemic index and new vessels in ultrawide-field fluorescein angiography images using automated software

2019 ◽  
pp. bjophthalmol-2018-313596 ◽  
Author(s):  
Gisung Son ◽  
Yoon Jeon Kim ◽  
Yu Sub Sung ◽  
Bumwoo Park ◽  
June-Gone Kim
Keyword(s):  
Diabetic Retinopathy ◽  
Fluorescein Angiography ◽  
Proliferative Diabetic Retinopathy ◽  
Diabetic Macular Oedema ◽  
Posterior Pole ◽  
Peripheral Retina ◽  
Foveal Thickness ◽  
Central Foveal Thickness ◽  
Treatment Naïve ◽  
Automated Software

Background/AimTo analyse ultrawide-field fluorescein angiography (UWF-FA) images of diabetic retinopathy using a novel software that automatically calculates microaneurysm (MA) and non-perfusion area.MethodsTwo hundred UWF-FA images of treatment-naïve diabetic retinopathy (38 proliferative diabetic retinopathy and 162 non-proliferative diabetic retinopathy) from 120 patients (mean age 54.22; 80 male) were analysed using novel software to determine the number of MAs, area of capillary non-perfusion (ischaemic index) and number of neovascularisations. Each result was compared according to its retinal regions.ResultsFor the total retina, the mean number of MAs was 292.02 (±175.57) and the ischaemic index was 59.42% (±14.78%). Most MAs were located in the mid-peripheral retina (80.54%); however, the density of MAs was highest in the posterior pole (p<0.001). The ischaemic index was highest in the peripheral retina (89.19%), followed by mid-periphery (50.65%) and posterior pole (1.85%). Patients with diabetic macular oedema (DME) presented more MA and a greater ischaemic index (p<0.001, each) than those without DME.ConclusionThe automated software allowed prompt and quantitative analysis of UWF-FA images of DMR. MAs were most frequent in the nasal and mid-peripheral retina, with their density being highest in the posterior pole and nasal retina. Ischaemic index increased with distance from the posterior pole, showing strong correlation with central foveal thickness in all retinal areas except the posterior pole.

scholarly journals Differential distribution of manifest lesions in diabetic retinopathy by fundus fluorescein angiography and fundus photography

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Xiaoli Li ◽  
Jie Xie ◽  
Liang Zhang ◽  
Ying Cui ◽  
Guanrong Zhang ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Fluorescein Angiography ◽  
Posterior Pole ◽  
Chinese Patients ◽  
Fundus Photography ◽  
Peripheral Retina ◽  
Multiple Logistic Regression ◽  
Fundus Fluorescein Angiography ◽  
Differential Distribution ◽  
Nonproliferative Diabetic Retinopathy

Abstract Background To analyze the distribution of manifest lesions of diabetic retinopathy (DR) by fundus fluorescein angiography (FFA) and color fundus photography (FP). Methods A total of 566 eyes of 324 Chinese patients diagnosed with DR were included in this retrospective study. DR severity was graded by the international grading criterion. The distributions of microaneurysms (MA), intraretinal hemorrhages/exudates (He/Ex), intraretinal microvascular abnormality (IRMA), capillary nonperfusion areas (NPA), and neovascularization (NV) were estimated by multiple logistic regression analyse based on nine-field FFA and FP images. Results In mild nonproliferative diabetic retinopathy (NPDR), the highest frequency of MA was found in the posterior pole (67.7%), followed by the inferior nasal (59.4%), and the nasal (55.4%) fields. In moderate NPDR, MA frequently distributed in the posterior pole (98.0%), nasal (97.0%), superior (96.0%), inferior nasal (94.9%), and inferior (92.9%) fields, whereas He/Ex were most prevalent in the posterior pole (69.7%). In severe NPDR and proliferative DR, IRMA, NPA, and NV were more frequent in the nasal field, particularly in the inferior nasal field (60.3, 38.7, and 76.0%, respectively). All lesions were more observed in the combined posterior pole, nasal, and inferior nasal fields than in the posterior pole or combined two fields in the early and severe stages of DR (P < 0.05). Conclusions The manifest lesions of DR were common in the nasal field besides the posterior pole in Chinese patients. A combined examination of the posterior pole, nasal, and inferior nasal mid-peripheral retina would help to detect different retinal lesions of DR. Trial registration ClinicalTrial. gov, NCT03528720. Registered 18 May 2018 - Retrospectively registered.

scholarly journals Relationships among Retinal Nonperfusion, Neovascularization, and Vascular Endothelial Growth Factor Levels in Quiescent Proliferative Diabetic Retinopathy

2020 ◽  
Vol 9 (5) ◽  
pp. 1462
Author(s):  
Ho Ra ◽  
Jae Hyun Park ◽  
Jin Uk Baek ◽  
Jiwon Baek
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Diabetic Retinopathy ◽  
Growth Factor ◽  
Aqueous Humor ◽  
Proliferative Diabetic Retinopathy ◽  
Peripheral Retina ◽  
Vascular Endothelial ◽  
Disc Area ◽  
Endothelial Growth Factor ◽  
Vegf Level

Purpose: To investigate the relationships among the retinal nonperfusion (NP) area, neovascularization (NV) area, and aqueous humor vascular endothelial growth factor (VEGF) levels in quiescent proliferative diabetic retinopathy (PDR). Methods: Forty-seven eyes from 47 patients with treatment-naïve PDR that did not show macular edema or vitreous hemorrhage were enrolled. NP area, NV number, and NV area were quantitatively measured using ultra-widefield fluorescein angiography in an automated manner. Aqueous humor VEGF level was measured using a bead assay. Results: The NP areas of the total, posterior pole, peripheral retinae, and NV area positively correlated with each other (all p < 0.034). NV number correlated with total NP area, peripheral NP area, and NV area (all p ≤ 0.001). VEGF levels were significantly positively correlated with total, posterior polar, and peripheral NP areas and NV area (r = 0.575, 0.422, 0.558, and 0.362, respectively; all p ≤ 0.012). In eyes with NV in the disc area, the VEGF level was higher compare to eyes without NV in the disc area (208.89 ± 192.77 pg/mL vs. 103.34 ± 132.66, p = 0.010). A multiple linear regression model using NP area, NV area, and NVD demonstrated good prediction for VEGF level (R2 = 0.417, p < 0.001) and revealed a significant contribution of the peripheral NP area in predicting the VEGF level (β = 0.497, p = 0.002). Conclusions: Aqueous humor VEGF levels in quiescent PDR eyes were associated with NP and NV areas, which had positive correlations with each other. In addition, the NP area of the peripheral retina was the most important predictor of VEGF level.

A NEW BIOMARKER QUANTIFYING THE EFFECT OF ANTI-VEGF THERAPY IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY ON ULTRA-WIDE FIELD FLUORESCEIN ANGIOGRAPHY

Retina ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Wenying Fan ◽  
Muneeswar Gupta Nittala ◽  
Charles c Wykoff ◽  
David M. Brown ◽  
Akihito Uji ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Fluorescein Angiography ◽  
Proliferative Diabetic Retinopathy ◽  
Wide Field ◽  
Anti Vegf

Longitudinal panretinal microaneurysm dynamics on ultra-widefield fluorescein angiography in eyes treated with intravitreal aflibercept for proliferative diabetic retinopathy in the recovery study

2020 ◽  
pp. bjophthalmol-2020-316952
Author(s):  
Amy Babiuch ◽  
Charles Clifton Wykoff ◽  
Jenna Hach ◽  
Sunil Srivastava ◽  
Katherine E Talcott ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Fluorescein Angiography ◽  
Proliferative Diabetic Retinopathy ◽  
Objective Measure ◽  
Significant Decline ◽  
Treatment Groups ◽  
Intravitreal Aflibercept ◽  
Registration Number ◽  
Recovery Study ◽  
A Prospective Study

Background/AimsQuantifying microaneurysms (MAs) turnover may be an objective measure for therapeutic response in diabetic retinopathy. This study assesses changes in MA counts on ultra-widefield fluorescein angiography (UWFA) in subjects undergoing treatment with intravitreal aflibercept injection (IAI) for proliferative diabetic retinopathy (PDR) in the Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy(RECOVERY) study using an automated MA detection platform.MethodsRECOVERY is a prospective study that enrolled 40 subjects with PDR randomised 1:1 to receive 2 mg IAI every 4 weeks(q4wk) or every 12 weeks (q12wk). UWFA images were obtained at baseline, 6 months and 1 year. Images were analysed using an automated segmentation platform to detect and quantify MAs. Zones 1, 2 and 3 correspond to the macula, mid-periphery and far-periphery, respectively.ResultsThe q4wk cohort demonstrated a significant decline in MAs in all zones and panretinally at baseline versus month 6, baseline versus year 1, and month 6 versus year 1 (−20.0% to −61.8%; all p<0.001). In the q12wk cohort, baseline versus month 6 showed a significant decline panretinally (mean: −34.2%; p<0.001) and in zone 3 (mean −44.18%; p<0.001). Addiitonally, baseline to year 1 in the q12wk group demonstrated significant decline panretinally (mean: −47.7%; p<0.001) and in zone 3 (mean: −59.8%; p<0.001). All zones demonstrated significantly decline from month 6 to year 1 in the q12wk group.ConclusionTherapy with IAI demonstrates significantly reduced panretinal MA counts in PDR at 1 year in both treatment groups. The use of automated platforms to detect and quantify MAs may provide a novel imaging marker for evaluating disease activity and therapeutic impact.Trial registration numberNCT02863354.

Sign in / Sign up

Export Citation Format

Share Document